Editorial: Targeted alpha particle therapy in oncology

Øyvind Sverre Bruland; Roy Hartvig Larsen; Richard Paul Baum; Asta Juzeniene

doi:10.3389/fmed.2023.1165747

Editorial: Targeted alpha particle therapy in oncology

Front Med (Lausanne). 2023 Mar 7;10:1165747. doi: 10.3389/fmed.2023.1165747. eCollection 2023.

Authors

Øyvind Sverre Bruland^{1

2}, Roy Hartvig Larsen³, Richard Paul Baum⁴, Asta Juzeniene^{5

6}

Affiliations

¹ Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
² Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
³ Sciencons AS, Oslo, Norway.
⁴ Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
⁵ Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
⁶ Department of Physics, University of Oslo, Oslo, Norway.

No abstract available

Keywords: actinium-225; astatine-211; lead-212; radium-223; radium-224; targeted alpha therapy (TAT); targeted radionuclide therapy (TRT); thorium-227.

Publication types

Editorial

Grant support

This research was funded by the South-Eastern Norway Regional Health Authority (project number 2020028, Oslo, Norway).